Piramal Pharma releases 2025–26 Sustainability Report

Piramal Pharma Limited has released its Sustainability Report 2025–26, detailing progress in environmental, social, and governance (ESG) priorities. The company reported a 22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions compared to its FY2022 baseline and increased renewable energy usage to 41% of its total energy consumption.

In terms of operational excellence, the company completed 38 regulatory inspections, including three USFDA inspections that resulted in zero Official Action Indicated (OAI) observations. Additionally, Piramal Pharma announced a $90 million investment to expand advanced therapeutics capabilities at its Lexington and Riverview facilities.

The report also highlights digital transformation efforts through SAP S/4HANA implementation and a commitment to social responsibility, noting an investment of 89.8 million rupees in CSR activities aimed at impacting approximately 1.8 million people through healthcare and education programs.